Skip to content
LATEST
Health

Arrowhead’s ARO-APOC3 adds Phase 2 dyslipidemia data

The registry entry creates a public checkpoint for a lipid-related drug candidate, without showing from this notice whether it is safe or effective.

Arrowhead's ARO-APOC3 adds Phase 2 dyslipidemia data

Arrowhead Pharmaceuticals’ ARO-APOC3 program added a completed Phase 2 dyslipidemia trial with results on ClinicalTrials.gov on Nov. 20, according to registry entry NCT05413135.

The Nov. 20 clinical registry update matters because Phase 2 trials test a therapeutic intervention in patients before any larger Phase 3 program; this record concerns adults with dyslipidemias, a group of lipid-related disorders.

ClinicalTrials.gov lists Arrowhead Pharmaceuticals as the sponsor of the trial. The intervention is ARO-APOC3, and the condition is dyslipidemias, according to the registry record.

The record’s NCT number is the ClinicalTrials.gov identifier, an eight-digit code used to track a registered clinical study. ClinicalTrials.gov defines a clinical trial as an interventional study involving human volunteers intended to add to medical knowledge.

The registry status does not by itself show that ARO-APOC3 improved lipid measures, reduced cardiovascular events or met any regulatory threshold. It also does not establish that the intervention is safe or effective for people outside the adults with dyslipidemias covered by the trial record.

For patients and clinicians, the practical significance is limited to trial progress and public availability of registry results. Any conclusions about efficacy, safety, dose or use would require the actual clinical data and regulatory review.

Source: clinical registry, ClinicalTrials.gov, Nov. 20, 2026

Atlas360 reports health research and does not provide medical advice.

More stories

Latest news